NewAmsterdam Pharma Company N.V. Derivative Liability, Noncurrent
NewAmsterdam Pharma Company N.V. (NAMS) had Derivative Liability, Noncurrent of $18.81 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2025-02-26
- 2024-09-30: Derivative Liability, Noncurrent $18.81M.
- 2024-06-30: Derivative Liability, Noncurrent $13.39M.
- 2024-03-31: Derivative Liability, Noncurrent $16.49M.
- 2023-12-31: Derivative Liability, Noncurrent $7.79M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2024-09-30 | $18.81M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $13.39M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $16.49M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $7.79M 10-K · filed 2025-02-26 |
| 2022-12-31 | $7.52M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |